Clobetasol Propionate is indicated in:
- Initial control of all forms of hyperacute eczema in all age groups
- Chronic hyperkeratotic eczema of the hands and feet and patches of chronic lichen simplex
- Chronic hyperkeratotic psoriasis of any area of the body
- Severe acute photosensitivity
- Hypertrophic lichen planus
- Localized bullous disorders
- Keloid scarring
- Pretibial myxoedema
- Suppression of reaction after cryotherapy
- Scalp Solution is indicated in the topical therapy of recalcitrant corticosteroid-responsive dermatoses of the scalp, including recalcitrant cases of psoriasis and seborrheic dermatitis.
Clobetasol / Clobetasone & Combined Preparations
Clobetasol has both local anti-inflammatory and immunosuppressive activity. The drug blocks the effect of macrophage migration inhibitory factor and decreases the activation of plasminogen to plasmin. Clobetasol also reduces the number of human leukocyte antigen & also inhibits phospholipase A2 activity via formation of lipocortin. Clobetasol reduces the formation of prostaglandins and leucotrienes in the local tissues.
Topical cream/ ointment:
Clobetasol should be applied with gentle rubbing to the affected skin areas twice daily. Dosage should not normally exceed 50 gm/ week and the duration of a course should not be more than 4 weeks. The potency can further enhanced by the use of occlusive dressing.
Scalp Solution: Apply required quantity of spray of Clobetasol Scalp Solution once or twice daily to the affected areas of the scalp and gently rub in. The total dose applied should not exceed 50 ml weekly. If necessary, Clobetasol Scalp Solution may be massaged into the scalp using the tips of the fingers. Therapy should be discontinued if no response is noted after one week or as soon as the lesion heals. It is advisable to use Clobetasol Scalp Solution for brief periods only.
Topical Spray: Clobetasol 0.05% topical spray is for topical use only, and not for ophthalmic, oral or intravaginal use. Spray should be sprayed directly onto the affected skin areas twice daily and rubbed in gently and completely. The total dosage should not exceed 50 g (59 ml or 2 fluid ounces) per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Do not use more than 26 sprays per application or 52 sprays per day.
Clobetasol 0.05% spray contains a topical corticosteroid; therefore treatment should be limited to 4 weeks. Therapy should be discontinued when control has been achieved. Treatment beyond 2 weeks should be limited to localized lesions of moderate to severe plaque psoriasis that have not sufficiently improved after the initial 2 weeks of treatment with Clobetasol Spray. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Before prescribing for more than 2 weeks, any additional benefits of extending treatment to 4 weeks should be weighed against the risk of HPA axis suppression.
Use in pediatric patients younger than 18 years is not recommended because of the potential for HPA axis suppression
No hazardous interactions have been reported with use of Clobetasol Propionate.
Contraindicated in Cutaneous infections such as impetigo, tinea corporis and herpes simplex, Infestations such as scabies, Acne vulgaris, Hypersensitivity, Rosacea, Gravitational ulceration, Perioral dermatitis, Children under 1 year
Generally this preparation is well tolerated. However, few side effects after prolonged and intensive treatment may cause local atrophic changes in the skin such as thinning, striae, and dilatation of the superficial blood vessels, particularly when occlusive dressings are used, or when skin folds are involved.
Clobetasol should be avoided in pregnant women, Mothers using large amounts of the drug should be aware of potential excretion in milk.
Avoid long-term therapy particularly in children, in whom adrenal suppression occurs readily. If Clobetasol is required for use in children, it is recommended that the treatment should be weekly reviewed. Avoid prolonged application to face because the face than other area of the body exhibits more atrophic changes with potent corticosteroids. Discontinue the use if there is spread of infection. Avoid contact with eyes.
Acute overdosage is very unlikely to occur, however, in the case of chronic overdosage or misuse the features of hypercortisolism may appear and in this situation topical steroids should be discontinued gradually.
Use in Paediatrics: The drug may be used in paediatrics patients in appropriate dosage, but large quantities for prolonged period should be avoided. It is contraindicated in children less than one year.
Store in a cool and dry place, away from light. Keep out of reach of children.